The Searle Company Limited held a corporate briefing session outlining its organizational structure, product categories, and recent financial performance, highlighting strong growth and profitability improvements.
- The session detailed the IBL Group's diversified business platform, including operations in pharmaceuticals, distribution, IT, and retail.
- Searle is ranked 1st in cardiovascular, gynecology, and cough suppressant categories, and is the fourth largest pharmaceutical company in Pakistan by units sold.
- FY 2026 standalone sales reached PKR 16.75B, with a profit after tax of PKR 31.64B, showing significant growth from FY 2025.
- Consolidated performance for FY 2026 also showed strong results with sales of PKR 36.81B and a return to profitability with a profit after tax of PKR 536M.
- Q1 FY 2027 consolidated sales increased by 31% year-on-year, with profit after tax rising to PKR 1.19B.
- The company continues to focus on expanding its product offerings across 16 therapeutic areas, ensuring broad market coverage and brand leadership.